This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
EV-302
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO GU 2025
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2024
ASCO GU 2024 Prostate Cancer
ASCO GU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
ASCO GU 2024 Prostate Cancer
Viewing 10501-10520 of 11881 articles
#AUA15 - Workplace dangers and safety for the urologist - Session Highlights
#AUA15 - Measuring success after radical cystectomy: feasibility of a novel composite endpoint (“poor recovery”) to quantify outcomes after surgery - Session Highlights
#AUA15 - MRI-fusion prostate biopsy in first-time biopsy cohort yields increased detection of clinically significant prostate cancer using a simplified MRI grading scale - Session Highlights
#AUA15 - Predictive value of plasma soluble Met protein concentration in patients with prostate cancer - Session Highlights
#AUA15 - Multiparametric magnetic resonance imaging and MRI/ultrasound fusion-guided biopsy predicts total tumor burden confirmed by whole mount prostatectomy - Session Highlights
#AUA15 - Effect of onabotulinumtoxinA treatment for neurogenic detrusor overactivity on the prevention of autonomic dysreflexia - Session Highlights
#AUA15 - Lack of sexual health knowledge among young males
#AUA15 - Long-term efficacy and safety of onobotulinumtoxinA in patients with neurogenic detrusor overactivity: Analysis among patients who completed 4 years of treatment - Session Highlights
#AUA15 - The natural history of targeted biopsy negative lesions identified on multiparametric magnetic resonance imaging - Session Highlights
#AUA15 - Upper tract urothelial carcinoma update - Session Highlights
#AUA15 - Crossfire: Controversies in Urology: Resolved - SWL should be retired - Session Highlights
#AUA15 - Evidence demonstrates long-term efficacy of botulinum toxin A treatment for neurogenic and non-neurogenic overactive bladder - Session Highlights
#AUA15 - Studies raise questions about appropriate urinary tract infection management
#AUA15 - Slide Presentation: Clinical utility of CCP test in personalizing prostate cancer treatment
#AUA15 - Poster: Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer
#AUA15 - Overactive bladder treatment linked to decreased fall risk for older adults
#AUA15 - Assessment of frailty helps doctors and patients plan better for surgery
#AUA15 - Studies evaluate effectiveness of active surveillance in prostate cancer patients
Myriad validates active surveillance threshold with Prolaris® for men with prostate cancer
#AUA15 - Crossfire: Controversies in Urology: Bladder sparing for invasive bladder cancer is not cancer sparing - Session Highlights
521
522
523
524
525
526
527
528
529
530
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free